Like Moderna before its COVID vaccine, but focused on developing a breakthrough drug for liver disease.

Like an early-stage Vertex Pharmaceuticals (known for specialized drugs), but focused on treatments for liver disease.

• Resmetirom: A liver-directed selective thyroid hormone receptor-ß agonist in Phase III clinical trials for non-alcoholic steatohepatitis (NASH).
• MGL-3745: A backup compound to resmetirom.

Bill Sibold, Chief Executive Officer and Director

Mr. Sibold has served as President and Chief Executive Officer of Madrigal Pharmaceuticals since September 2023, bringing over 30 years of experience in the biopharmaceutical industry. Prior to joining Madrigal, he was the Executive Vice President, Specialty Care of Sanofi and President, Sanofi North America from 2017 to September 2023, where he led a global organization of approximately 10,000 employees and was a member of the Sanofi Executive Committee. During his tenure at Sanofi, Specialty Care achieved sustained double-digit growth, and he was instrumental in the launch of Dupixent. His previous leadership roles include Chief Commercial Officer of Avanir Pharmaceuticals, President and CEO of Lycera Corp., and Senior Vice President, U.S. Commercial for Biogen.

Mardi C. Dier, Executive Vice President, Chief Financial Officer

Ms. Dier was appointed Chief Financial Officer of Madrigal Pharmaceuticals on March 11, 2024. She possesses over 20 years of experience in executive financial leadership within the biopharmaceutical industry, with extensive expertise in operational and strategic decision-making, capital raising, financial planning and accounting, global supply chain management, investor relations, and business development. Before joining Madrigal, Ms. Dier served as Chief Financial Officer at Portola Pharmaceuticals, Ultragenyx Pharmaceutical, Inc., and Acelyrin, Inc.

Rebecca Taub, M.D., Founder and Director; Senior Scientific and Medical Advisor

Dr. Taub co-founded Madrigal Pharmaceuticals in 2011 with a vision to address unmet medical needs for patients with serious liver and cardiometabolic diseases. She transitioned to Senior Scientific and Medical Advisor effective April 21, 2025, and continues to serve on Madrigal's Board of Directors. Previously, Dr. Taub served as the company's President, Research & Development from June 2019 and Chief Medical Officer from July 2016. She also held the role of Chief Executive Officer of privately-held Madrigal Pharmaceuticals from its inception in September 2011 until July 2016. Her background includes roles as Senior Vice President, Research and Development of VIA Pharmaceuticals, Inc. (2008-2011) and Vice President, Research, Metabolic Diseases at F. Hoffmann-La Roche (2004-2008). Dr. Taub was also a tenured Professor of Genetics and Medicine at the University of Pennsylvania. Under her leadership, Madrigal achieved the development of Rezdiffra™ (resmetirom), the first FDA-approved medicine for MASH.

Mark Barrett, Executive Vice President, Chief Business Officer

Mr. Barrett joined Madrigal Pharmaceuticals in January 2024, bringing more than 25 years of executive leadership and biopharmaceutical industry experience. He has a proven track record of successfully completing a wide range of partnerships and acquisitions to build commercial portfolios and R&D pipelines. Prior to Madrigal, he was a Co-founder, CEO, and Director of Lassen Therapeutics, a biotechnology company focused on novel antibody therapeutics. Mr. Barrett also served as an Entrepreneur in Residence at Frazier Healthcare Partners, where he focused on establishing and financing new biotech companies.

Neil Archer, Executive Vice President, International

Mr. Archer serves as Madrigal Pharmaceuticals' Executive Vice President, International. Specific background details for Mr. Archer were not available in the provided search results.

Key Risks to Madrigal Pharmaceuticals (MDGL)

1. Heavy Dependence on a Single Product: Madrigal Pharmaceuticals' business is substantially dependent on the successful commercialization and continued success of its lead product, Rezdiffra (resmetirom), which currently represents the overwhelming majority of its revenue. This creates a significant "single point of failure risk" where any material adverse event impacting Rezdiffra, such as manufacturing or supply chain disruptions, the emergence of superior competitive products, unforeseen regulatory actions, or unexpected post-launch side effects, could severely undermine the company's financial performance and future prospects.
2. Intense Competitive Pressures in the MASH Market: The market for Metabolic Dysfunction-Associated Steatohepatitis (MASH), formerly known as NASH, is highly competitive and rapidly evolving. Madrigal Pharmaceuticals faces substantial competition from other pharmaceutical companies, including large players like Eli Lilly and Novo Nordisk, who are developing or have approved GLP-1 agonists with potential applications in MASH. These competitors could introduce alternative or superior treatments, leading to intense pricing pressure, erosion of market share, and lower-than-expected peak sales for Rezdiffra.
3. Uncertainties in Market Acceptance and Commercialization Challenges: Despite Rezdiffra receiving accelerated approval, there are inherent uncertainties regarding its broad market acceptance by physicians, patients, and third-party payers. Challenges in achieving anticipated market penetration, accurately estimating the potential market size, and securing adequate reimbursement and support from the medical community could limit Rezdiffra's commercial success. These factors pose significant commercialization risks that could hinder revenue growth and profitability.

Madrigal Pharmaceuticals' primary product, resmetirom (marketed as Rezdiffra), targets the treatment of non-alcoholic steatohepatitis (NASH), now often referred to as metabolic dysfunction-associated steatohepatitis (MASH), specifically for adults with noncirrhotic MASH with moderate to advanced liver fibrosis (consistent with stages F2 to F3 fibrosis).

The addressable market for NASH/MASH treatments is substantial and rapidly growing:

• Global Market: The global NASH treatment market was valued at approximately USD 2.114 billion in 2023. It is projected to grow significantly, with various estimates pointing to a market size of USD 31.76 billion by 2033, growing at a compound annual growth rate (CAGR) of 17.7% from 2025 to 2033. Other projections suggest the global market could reach USD 55.52 billion by 2032 with a CAGR of 28.05% from 2025 to 2032. Some analyses even indicate a potential global market worth up to USD 108.4 billion by 2030.
• U.S. Market: The United States represented the largest share of the NASH market among the 7 major markets (7MM), valued at approximately USD 1.519 billion in 2023. The U.S. non-alcoholic steatohepatitis treatment market was valued at USD 4.56 billion in 2024 and is expected to reach USD 32.55 billion by 2032, with a CAGR of 27.88%. Madrigal Pharmaceuticals is focused on approximately 315,000 patients in the U.S. with moderate to advanced fibrosis (F2-F3) who are under the care of liver specialists. For patients with compensated MASH cirrhosis (stage F4c), the estimated market opportunity in the U.S. includes approximately 245,000 diagnosed patients under the care of a liver specialist. The approved drug segment, which primarily includes Rezdiffra as the first approved therapy, reached USD 178.31 million in 2024 and is expected to surge to USD 16.82 billion by 2033. The U.S. NASH market alone could be worth USD 15 billion by 2027.

Madrigal Pharmaceuticals (NASDAQ: MDGL) is poised for significant revenue growth over the next two to three years, driven primarily by the continued commercial success and expansion of its lead product, Rezdiffra (resmetirom), the first and only FDA-approved therapy for metabolic dysfunction-associated steatohepatitis (MASH) with moderate to advanced liver fibrosis.

Here are the key expected drivers of future revenue growth:

1. Continued U.S. Market Penetration and Patient Adoption for Rezdiffra: Since its FDA approval in March 2024, Rezdiffra has demonstrated exceptional launch performance and strong demand in the U.S. market. By the end of Q4 2025, over 36,250 patients were on Rezdiffra therapy. Madrigal anticipates steadily increasing patient numbers and expanding its market presence, with broad first-line insurance access and no step-edit requirements secured for 2026, positioning Rezdiffra as a foundational therapy for F2 to F3 MASH. The U.S. market remains the primary growth engine for the company.
2. International Expansion with Rezdiffra Launch in Europe: Madrigal is awaiting regulatory approval for Rezdiffra from the European Medicines Agency (EMA), with a decision anticipated by mid-2025. Following approval, the company plans a country-by-country launch in Europe, commencing with Germany in the second half of 2025. The European market for MASH patients with F2/F3 fibrosis is estimated to be larger than in the U.S., presenting a substantial opportunity for revenue growth over the next 2-3 years as the product gains traction across the continent.
3. Potential Label Expansion for Rezdiffra in Compensated MASH Cirrhosis (F4c): Madrigal is actively pursuing an expanded indication for Rezdiffra to treat patients with compensated MASH cirrhosis. Positive two-year data from the Phase 3 MAESTRO-NAFLD-1 trial in this population suggest Rezdiffra's potential to become the first approved treatment for this advanced stage of MASH. The results from the pivotal MAESTRO-NASH OUTCOMES trial, expected in 2027, could lead to a label expansion, significantly broadening the addressable patient population and establishing Rezdiffra as one of the few MASH drugs with hepatic outcomes data.
4. Development and Launch of Rezdiffra-Based Combination Therapies: Madrigal is strategically expanding its pipeline through in-licensing deals for additional MASH therapeutics, including an oral GLP-1 receptor agonist (MGL-2086) and a Phase 2 oral DGAT-2 inhibitor (ervogastat). The company's focus is on developing combination therapies, anchored by Rezdiffra, to address diverse patient subtypes and genetic drivers of MASH. The oral GLP-1 combination program is slated to begin in the first half of 2026, offering potential for new revenue streams through enhanced treatment options.

Share Issuance

• Madrigal Pharmaceuticals' shares outstanding increased by 5.46% in 2025, 13.83% in 2024, and 9.05% in 2023, reflecting ongoing share issuances.
• The company registered 300,000 shares of common stock for issuance under its 2025 Inducement Stock Plan to grant equity awards to new hires.
• Equity awards, including options and restricted stock units, were granted to new non-executive employees in March 2026 and to the new Chief Accounting Officer in January 2026 under the 2025 Inducement Plan.

Inbound Investments

• In July 2025, Madrigal entered into a senior secured credit facility with funds managed by Blue Owl Capital, providing access to up to $500 million. An initial term loan of $350 million was funded at closing, with a portion used to repay a prior loan facility.

Outbound Investments

• On July 30, 2025, Madrigal signed an exclusive global license agreement with CSPC Pharmaceutical Group for SYH2086, an oral GLP-1 receptor agonist, which included an upfront payment of $120 million and potential milestone payments up to $2 billion.
• In February 2026, the company licensed global rights to six preclinical siRNA programs, involving an upfront payment of $60 million.
• Madrigal expanded its pipeline by licensing a Phase 2 oral DGAT-2 inhibitor, ervogastat, aiming to develop combination therapies with Rezdiffra.

Capital Expenditures

• Madrigal Pharmaceuticals' capital expenditures for the full year 2025 were approximately $467K.